Stephanie B Dixon1, Yan Chen2, Yutaka Yasui3, Ching-Hon Pui1, Stephen P Hunger4, Lewis B Silverman5, Kirsten K Ness3, Daniel M Green1, Rebecca M Howell6, Wendy M Leisenring7, Nina S Kadan-Lottick8, Kevin R Krull3,9, Kevin C Oeffinger10, Joseph P Neglia11, Ann C Mertens12, Melissa M Hudson1,3, Leslie L Robison3, Gregory T Armstrong3, Paul C Nathan13. 1. Department of Oncology, St Jude Children's Research Hospital, Memphis, TN. 2. School of Public Health, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN. 4. Division of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA. 5. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA. 6. Radiation Physics Department, The University of Texas at MD Anderson Cancer Center, Houston, TX. 7. Cancer Prevention and Clinical Statistics Programs, Fred Hutchinson Cancer Research Center, Seattle, WA. 8. Department of Pediatric Hematology/Oncology, Yale Cancer Center, New Haven, CT. 9. Department of Psychology, St Jude Children's Research Hospital, Memphis, TN. 10. Department of Medicine, Duke University, Durham, NC. 11. Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN. 12. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA. 13. Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE: Risk-stratified therapy, which modifies treatment on the basis of clinical and biologic features, has improved 5-year overall survival of childhood acute lymphoblastic leukemia (ALL) to 90%, but its impact on long-term toxicity remains unknown. METHODS: We assessed all-cause and health-related late mortality (including late effects of cancer therapy), subsequent malignant neoplasms (SMNs), chronic health conditions, and neurocognitive outcomes among 6,148 survivors of childhood ALL (median age, 27.9 years; range, 5.9-61.9 years) diagnosed between 1970 and 1999. Therapy combinations and treatment intensity defined 6 groups: 1970s-like (70s), standard- or high-risk 1980s-like (80sSR, 80sHR) and 1990s-like (90sSR, 90sHR), and relapse/transplantation (R/BMT). Cumulative incidence, standardized mortality ratios, and standardized incidence ratios were compared between treatment groups and with the US population. RESULTS: Overall, 20-year all-cause late mortality was 6.6% (95% CI, 6.0 to 7.1). Compared with 70s, 90sSR and 90sHR experienced lower health-related late mortality (rate ratio [95% CI]: 90sSR, 0.2 [0.1 to 0.4]; 90sHR, 0.3 [0.1 to 0.7]), comparable to the US population (standardized mortality ratio [95% CI]: 90sSR, 1.3 [0.8 to 2.0]; 90sHR, 1.7 [0.7 to 3.5]). Compared with 70s, 90sSR had a lower rate of SMN (rate ratio [95% CI], 0.3 [0.1 to 0.6]) that was not different from that of the US population (standardized incidence ratio [95% CI], 1.0 [0.6 to 1.6]). The 90sSR group had fewer severe chronic health conditions than the 70s (20-year cumulative incidence [95% CI], 11.0% [9.7% to 12.3%] v 22.5% [19.4% to 25.5%]) and a lower prevalence of impaired memory (prevalence ratio [95% CI], 0.7 [0.6 to 0.9]) and task efficiency (0.5 [0.4 to 0.7]). CONCLUSION: Risk-stratified therapy has reduced late morbidity and mortality among contemporary survivors of standard-risk ALL, represented by 90sSR. Health-related late mortality and SMN risks among 5-year survivors of contemporary, standard-risk childhood ALL are comparable to the general population.
PURPOSE: Risk-stratified therapy, which modifies treatment on the basis of clinical and biologic features, has improved 5-year overall survival of childhood acute lymphoblastic leukemia (ALL) to 90%, but its impact on long-term toxicity remains unknown. METHODS: We assessed all-cause and health-related late mortality (including late effects of cancer therapy), subsequent malignant neoplasms (SMNs), chronic health conditions, and neurocognitive outcomes among 6,148 survivors of childhood ALL (median age, 27.9 years; range, 5.9-61.9 years) diagnosed between 1970 and 1999. Therapy combinations and treatment intensity defined 6 groups: 1970s-like (70s), standard- or high-risk 1980s-like (80sSR, 80sHR) and 1990s-like (90sSR, 90sHR), and relapse/transplantation (R/BMT). Cumulative incidence, standardized mortality ratios, and standardized incidence ratios were compared between treatment groups and with the US population. RESULTS: Overall, 20-year all-cause late mortality was 6.6% (95% CI, 6.0 to 7.1). Compared with 70s, 90sSR and 90sHR experienced lower health-related late mortality (rate ratio [95% CI]: 90sSR, 0.2 [0.1 to 0.4]; 90sHR, 0.3 [0.1 to 0.7]), comparable to the US population (standardized mortality ratio [95% CI]: 90sSR, 1.3 [0.8 to 2.0]; 90sHR, 1.7 [0.7 to 3.5]). Compared with 70s, 90sSR had a lower rate of SMN (rate ratio [95% CI], 0.3 [0.1 to 0.6]) that was not different from that of the US population (standardized incidence ratio [95% CI], 1.0 [0.6 to 1.6]). The 90sSR group had fewer severe chronic health conditions than the 70s (20-year cumulative incidence [95% CI], 11.0% [9.7% to 12.3%] v 22.5% [19.4% to 25.5%]) and a lower prevalence of impaired memory (prevalence ratio [95% CI], 0.7 [0.6 to 0.9]) and task efficiency (0.5 [0.4 to 0.7]). CONCLUSION: Risk-stratified therapy has reduced late morbidity and mortality among contemporary survivors of standard-risk ALL, represented by 90sSR. Health-related late mortality and SMN risks among 5-year survivors of contemporary, standard-risk childhood ALL are comparable to the general population.
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: A Möricke; M Zimmermann; A Reiter; G Henze; A Schrauder; H Gadner; W D Ludwig; J Ritter; J Harbott; G Mann; T Klingebiel; F Zintl; C Niemeyer; B Kremens; F Niggli; D Niethammer; K Welte; M Stanulla; E Odenwald; H Riehm; M Schrappe Journal: Leukemia Date: 2009-12-10 Impact factor: 11.528
Authors: Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Neuropsychology Date: 2014-06-16 Impact factor: 3.295
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: L B Silverman; K E Stevenson; J E O'Brien; B L Asselin; R D Barr; L Clavell; P D Cole; K M Kelly; C Laverdiere; B Michon; M A Schorin; C L Schwartz; E W O'Holleran; D S Neuberg; H J Cohen; S E Sallan Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528
Authors: Philippe Hernigou; Jean Charles Auregan; Arnaud Dubory; Charles Henri Flouzat Lachaniette; Hélène Rouard Journal: Int Orthop Date: 2021-04-23 Impact factor: 3.075
Authors: Rozalyn L Rodwin; John A Kairalla; Emily Hibbitts; Meenakshi Devidas; Moira K Whitley; Caroline E Mohrmann; Reuven J Schore; Elizabeth Raetz; Naomi J Winick; Stephen P Hunger; Mignon L Loh; Marilyn J Hockenberry; Anne L Angiolillo; Kirsten K Ness; Nina S Kadan-Lottick Journal: J Natl Cancer Inst Date: 2022-08-08 Impact factor: 11.816
Authors: Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090
Authors: Kateryna Petrykey; Aziz M Rezgui; Mathilde Le Guern; Patrick Beaulieu; Pascal St-Onge; Simon Drouin; Laurence Bertout; Fan Wang; Jessica L Baedke; Yutaka Yasui; Melissa M Hudson; Marie-Josée Raboisson; Caroline Laverdière; Daniel Sinnett; Gregor U Andelfinger; Maja Krajinovic Journal: Pharmacogenomics Date: 2021-09-10 Impact factor: 2.638
Authors: Gregory T Armstrong; Paul C Nathan; Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Melissa M Hudson; Leslie L Robison; Ann C Mertens Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-25 Impact factor: 4.090